Liquidia Technologies, Inc. (NASDAQ:LQDA) Insider Sells $76,069.56 in Stock

Liquidia Technologies, Inc. (NASDAQ:LQDA - Get Free Report) insider Rajeev Saggar sold 5,327 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $14.28, for a total value of $76,069.56. Following the completion of the sale, the insider directly owned 271,413 shares of the company's stock, valued at $3,875,777.64. This represents a 1.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Rajeev Saggar also recently made the following trade(s):

• On Monday, April 21st, Rajeev Saggar sold 2,450 shares of Liquidia Technologies stock. The stock was sold at an average price of $13.67, for a total value of $33,491.50.

Liquidia Technologies Stock Performance

LQDA stock traded down $0.20 on Friday, reaching $14.41. The company's stock had a trading volume of 929,859 shares, compared to its average volume of 1,301,913. Liquidia Technologies, Inc. has a 52 week low of $8.26 and a 52 week high of $19.41. The company has a market capitalization of $1.23 billion, a P/E ratio of -9.14 and a beta of -0.01. The firm has a fifty day moving average of $14.88 and a two-hundred day moving average of $14.48. The company has a debt-to-equity ratio of 2.08, a current ratio of 2.93 and a quick ratio of 2.91.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.03). The firm had revenue of $3.12 million for the quarter, compared to the consensus estimate of $3.23 million. Liquidia Technologies had a negative net margin of 903.80% and a negative return on equity of 177.91%. As a group, analysts predict that Liquidia Technologies, Inc. will post -1.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LQDA has been the subject of a number of analyst reports. Raymond James Financial boosted their price target on Liquidia Technologies from $27.00 to $29.00 and gave the stock a "strong-buy" rating in a report on Friday, May 9th. Wall Street Zen raised Liquidia Technologies from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. HC Wainwright boosted their price target on Liquidia Technologies from $29.00 to $35.00 and gave the company a "buy" rating in a research report on Wednesday, May 28th. Oppenheimer set a $13.00 price objective on Liquidia Technologies and gave the stock an "underperform" rating in a research note on Monday, May 19th. Finally, Bank of America cut their price target on Liquidia Technologies from $25.00 to $23.00 and set a "buy" rating on the stock in a research note on Wednesday, June 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $26.89.

Institutional Trading of Liquidia Technologies

A number of hedge funds have recently modified their holdings of LQDA. Vanguard Group Inc. increased its stake in shares of Liquidia Technologies by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 3,557,296 shares of the company's stock worth $41,834,000 after acquiring an additional 115,367 shares during the last quarter. LM Advisors LLC acquired a new stake in shares of Liquidia Technologies in the fourth quarter valued at about $25,948,000. Whitefort Capital Management LP lifted its stake in shares of Liquidia Technologies by 16.8% in the fourth quarter. Whitefort Capital Management LP now owns 1,987,245 shares of the company's stock valued at $23,370,000 after buying an additional 285,220 shares during the period. Vestal Point Capital LP lifted its stake in shares of Liquidia Technologies by 17.3% in the fourth quarter. Vestal Point Capital LP now owns 1,760,000 shares of the company's stock valued at $20,698,000 after buying an additional 260,000 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Liquidia Technologies by 8.2% in the fourth quarter. Geode Capital Management LLC now owns 1,339,254 shares of the company's stock valued at $15,753,000 after buying an additional 101,597 shares during the period. Hedge funds and other institutional investors own 64.54% of the company's stock.

Liquidia Technologies Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).